Research Alliance Corp III
corporate_fare Company Profile
Research Alliance Corp III (NASDAQ:RACC) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 15 items for RACC at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-30, rated 8/10. Across its 15 most recent items scored 7 or higher, the top rating is 9/10, with 9 rated 8 or above. Recent SEC coverage for RACC spans S-4/A, 425, S-4, 10-Q.
Recent high-impact activity:
- RACC Sets Nov 24 Vote on Oak Hill Bio Merger; $55M PIPE and $75M Backstop in Place
- S-4/A Filing Advances Oak Hill Bio Merger as Scalar Flags $9M Net Cash Correction
- Oak Hill Bio Investor Deck Reveals Rugonersen Phase 3 Trial Design and New Efficacy Data
- Rival Angelman Drug Fails Phase 3; Oak Hill Bio's Rugonersen Seen as More Potent
- RACC Files S-4 for Oak Hill Bio Merger: $55M PIPE, $75M Backstop, 42.4% Target Ownership
Short Interest & Short Volume
1.00 days to coverFINRA reported short interest of 7,587 shares in RACC as of the October 30, 2026 settlement, a 12.3% decrease from the prior period — about 1.0 days to cover at its recent average daily volume. On November 20, 2026, 97.3% of RACC volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.